Some Parkinson’s disease patients with a specific genetic variant have widespread reduction of gray matter in dementia-related brain regions.
Category: biotech/medical – Page 2,554
Bioquark Inc. — Creatively Speaking Radio — Ira Pastor
Thanks so much to Luanna Helena for having me on Creatively Speaking Radio to discuss Bioquark Inc. (http://www.bioquark.com) and nature’s clues for human regeneration, disease reversion, and age rejuvenation -
Also got to introduce our new mosquito / “ectocrinome” research program — (https://www.bizjournals.com/philadelphia/news/2019/01/02/bio…nefit.html) —
http://blogtalkradio.com/creativelyspeaking/2019/01/12/episode-79-ira-pastor
Quantum computing explained in 10 minutes
A quantum computer isn’t just a more powerful version of the computers we use today; it’s something else entirely, based on emerging scientific understanding — and more than a bit of uncertainty. Enter the quantum wonderland with TED Fellow Shohini Ghose and learn how this technology holds the potential to transform medicine, create unbreakable encryption and even teleport information.
What does it mean to be posthuman?
Bioscience and medical technology are propelling us beyond the old human limits. Are Extremes and The Posthuman good guides to this frontier?
By David Cohen
HOW would you like to be a posthuman? You know, a person who has gone beyond the “maximum attainable capacities by any current human being without recourse to new technological means”, as philosopher Nick Bostrum of the Future of Humanity Institute at the University of Oxford so carefully described it in a recent paper.
Anticipation Is Growing for Undoing Aging 2019
As the new year begins, we approach one of the most awaited life extension events of 2019: the Undoing Aging conference.
Starting off with a success
The Undoing Aging conference series started off in 2018, with the first being held in Berlin, Germany, in mid-March. Especially when you consider that UA2018 was the inaugural event of the series, it was extremely successful; the three-day conference organized by SENS Research Foundation (SRF) and Forever Healthy Foundation (FHF) brought together many of the most illustrious experts in the fields of aging research, biotechnology, regenerative medicine, AI for drug discovery, advocacy and policy, and business and investment.
Staphylococcus aureus: Study describes development of resistance to antibiotic for the first time
The Staphylococcus aureus bacterium is one of the commonest pathogens and can even cause sepsis. The new antibiotic dalbavancin is very effective against many bacterial pathogens. However, resistance to the antibiotic was seen to develop during the long-term treatment of a patient with an infection caused by an implanted cardiac device. A team of researchers led by infectiologists from the Division of Infectious Diseases and Tropical Medicine within the Department of Medicine I at MedUni Vienna, Manuel Kussmann and Heimo Lagler, have now described the phenotypical and genotypical mechanism of this development of resistance for the first time. The study was published in leading journal “Emerging Microbes & Infections”.
Staphylococci are bacteria and are part of the normal flora on the skin of humans and animals. Approximately 20% of the Austrian population permanently carry the germ, which is often located in the nasal cavity. There are harmless variants, which only cause mild symptoms, if any at all. In serious cases, the pathogen can find its way into the bloodstream and cause endocarditis and sepsis.
A problematic strain is Staphylococcus aureus, which can be acquired outside hospital but also in hospital as a so-called “hospital-acquired infection”. There are multi-resistant forms of it, which do not necessarily cause serious illness in healthy people. However, in weakened hospital patients or where the natural skin barrier is damaged, infection can result in complications. Nowadays dalbavancin, a latest generation antibiotic, is one of the drugs successfully used to treat multi-resistant bacteria. One of the advantages of this drug is its very long half-life of approximately nine days, so that intravenous treatment can be given on an outpatient basis. However, clinical experience has shown that, sooner or later, resistance develops to any therapeutic use of new antibiotics, so it was just a matter of time with this one.
